A Phase 2 interventional study of Ciliary neurotrophic factor (CNTF) and Sham procedure in Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-12.
Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Telangiectasis with a site in United States — 5 open to participants now, 5 under way, 2 of them phase 3. Telangiectasis · United States.
Among the 33 studies in Telangiectasis with a site in United States, this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 14th registered.
69 studies on the registry are indexed under Telangiectasis; 12 are open to participants now.
Browse Telangiectasis studies →5 of the 33 studies in Telangiectasis with a site in United States are open now. Recruiting first, the newest first:
Atavistik Bio, Inc · Sites in United States, Argentina
Ages 18+ · Healthy volunteers
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 18+
Neurotech Pharmaceuticals · Sites in United States, Australia
Ages 21–80
Cure HHT · Sites in United States
Healthy volunteers
The Lowy Medical Research Institute Limited · Sites in United States, Australia, Germany and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Telangiectasis studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 30 across 59 interventional studies indexed under Telangiectasis.
Median enrollment 20 across the 31 interventional studies, 5,011 across the 2 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Neurotech Pharmaceuticals has 7 studies filed under Telangiectasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Telangiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
Biological: Ciliary neurotrophic factor (CNTF) · Device: NT-501 Implant · Procedure: NT-501 Implant procedure
Non-penetrating sham procedure to mimic implant procedure
Procedure: Sham procedure
Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
Sham surgery for Sham arm
NT-501 encapsulated cell implant
Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
Ellipsoid zone (area of IS/OS loss) as measured by en face imagining by SDOCT in study eye(s)
Change in the ellipsoid zone (area of IS/OS loss) from baseline to month 24 as measured by en face imaging by SDOCT in study eye(s)
Time frame: 24 months
Ellipsoid zone
Change in the ellipsoid zone from baseline to Month 12.
Time frame: 12 months
Retinal sensitivity (dB) as measured by microperimetry
Change in retinal sensitivity (dB) as measured by microperimetry from baseline to Months 12 and 24.
Time frame: 12 and 24 months
Increase in ellipsoid zone
Proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone at Months 12 and 24.
Time frame: 12 and 24 months
Visual Acuity
Change in best corrected visual acuity (BCVA) from baseline to Months 12 and 24.
Time frame: 12 and 24 months
Visual Acuity
Proportion of study eyes with 15 or more letter loss from baseline in BCVA at Months 12 and 24.
Time frame: 12 and 24 Months
Visual Acuity
Proportion of study eyes with 10 or more letter loss from baseline in BCVA at Months 12 and 24.
Time frame: 12 and 24 Months
Reading Speed
Change in reading speed as measured by the IReST from baseline to Months 12 and 24.
Time frame: 12 and 24 Months
Cone density as measured by AOSLO
Change in cone density as measured by AOSLO from baseline to Months 12 and 24, in selected participants.
Time frame: 12 and 24 Months
National Eye Institute Visual Functioning Questionnaire
Change in NEI VFQ (overall and subscale) from baseline to Months 12 and 24.
Time frame: 12 and 24 months
Electroretinogram changes
Electroretinogram (ERG) changes from baseline to Months 6, 12 and 24, in selected clinics/participants.
Time frame: 6, 12 and 24 Months
The record gives a start of Apr 2014, a primary completion of Apr 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciliary Neurotrophic Factor
Neurotech Pharmaceuticals